Abstract
During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (M pro ) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.
【초록키워드】 COVID-19, Treatment, coronavirus disease, SARS-CoV-2, Coronavirus disease 2019, Efficacy, pandemic, Depression, clinical trials, drug, protease, in vitro, MERS, antidepressants, FDA-approved drugs, anti-SARS-CoV-2, MERS-CoV, Anti-viral, activity, Prophylaxis, Patient, eating disorders, in vivo, COVID-19 patients, Anti-SARS-CoV-2 Activity, antidepressant, migraine, imipramine, amitriptyline, disorders, FDA-approved drug, Molecular docking study, M pro, activities, treating COVID-19, disorder, molecular docking studies, FIVE, effective, sertraline, neuralgia, Paroxetine, Result, performed, evaluated, eight, suggested, reported symptom, symptomatic and asymptomatic, symptoms of depression, 【제목키워드】 in vitro, antiviral activity, in silico,